Sangamo Therapeutics Stock In The News

SGMO Stock  USD 0.92  0.02  2.13%   
Our overall analysis of Sangamo Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Sangamo Therapeutics. The specific impact of Sangamo Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Sangamo Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Sangamo Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Sangamo Therapeutics Backtesting and Sangamo Therapeutics Hype Analysis.
To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.

Sangamo Therapeutics Today Top News and Investor Outlook

Yahoo News
Market Today: Tech Giants and Biotech Suffer Amid Market Retreat
https://finance.yahoo.com/news/market-today-tech-giants-biotech-210554801.html
 Neutral
Yahoo News
Companies Like Sangamo Therapeutics (NASDAQ:SGMO) Could Be Quite Risky
https://finance.yahoo.com/news/companies-sangamo-therapeutics-nasdaq-sgmo-134903807.html
 Neutral
Yahoo News
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2023 Earnings Call Transcript
https://finance.yahoo.com/news/sangamo-therapeutics-inc-nasdaq-sgmo-210347884.html
 Bullish
Yahoo News
Sangamo Therapeutics Inc (SGMO) Announces Q3 2023 Financial Results and Strategic Update
https://finance.yahoo.com/news/sangamo-therapeutics-inc-sgmo-announces-230555925.html
 Neutral
Yahoo News
Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results
https://finance.yahoo.com/news/sangamo-therapeutics-announces-strategic-reports-200100138.html
 Neutral
Yahoo News
Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
https://finance.yahoo.com/news/sangamo-therapeutics-sgmo-may-report-140205350.html
 Bullish
Yahoo News
Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
https://finance.yahoo.com/news/sangamo-therapeutics-announces-third-quarter-201500199.html
 Neutral
Yahoo News
Sangamo Therapeutics to Present Pre-Clin...
https://finance.yahoo.com/news/sangamo-therapeutics-present-pre-clinical-060100779.html
 Neutral
Yahoo News
Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit
https://finance.yahoo.com/news/sangamo-therapeutics-present-jefferies-cell-201500252.html
 Neutral
Yahoo News
Recent uptick might appease Sangamo Therapeutics, Inc. (NASDAQ:SGMO) institutional owners after losing 82% over the past year
https://finance.yahoo.com/news/recent-uptick-might-appease-sangamo-175259854.html
 Bullish

Sangamo Therapeutics Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Sangamo and other traded companies coverage with news coverage. We help investors stay connected with Sangamo headlines for the 20th of October to make an informed investment decision based on correlating the impacts of news items on Sangamo Stock performance. Please note that trading solely based on the Sangamo Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Sangamo Therapeutics' linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Sangamo Therapeutics investors visualize upcoming and past events in order to time the market based on Sangamo Therapeutics noise-free hype analysis.
Sangamo Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Sangamo earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Sangamo Therapeutics that are available to investors today. That information is available publicly through Sangamo media outlets and privately through word of mouth or via Sangamo internal channels. However, regardless of the origin, that massive amount of Sangamo data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Sangamo Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Sangamo Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Sangamo Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Sangamo Therapeutics alpha.

Sangamo Largest EPS Surprises

Earnings surprises can significantly impact Sangamo Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2010-07-28
2010-06-30-0.08-0.09-0.0112 
2003-04-29
2003-03-31-0.1-0.11-0.0110 
2002-10-30
2002-09-30-0.09-0.1-0.0111 
2002-02-05
2001-12-31-0.07-0.08-0.0114 
2018-11-08
2018-09-30-0.15-0.130.0213 
2018-08-08
2018-06-30-0.15-0.17-0.0213 
View All Earnings Estimates

Sangamo Therapeutics Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Sangamo Therapeutics Stock. The global stock market is bullish. About 68% of major world exchanges and indexes are currently up. See today's market update for more information.
Macroaxis News
15th of October 2024
Acquisition by Horn Margaret A of 13900 shares of Sangamo Therapeutics subject to Rule 16b...
at MacroaxisInsider 
Google News at Macroaxis
27th of September 2024
Sangamo Therapeutics Stock Price Crosses Above 200 Day Moving Average of 0.64 - MarketBeat
at news.google.com 
Macroaxis News
13th of August 2024
Disposition of 892 shares by Scott Willoughby of Sangamo Therapeutics at 0.9751 subject to...
at MacroaxisInsider 
Yahoo News
9th of August 2024
Sangamo Therapeutics, Inc. Just Reported And Analysts Have Been Lifting Their Price Target...
at finance.yahoo.com 
insidermonkey News
7th of August 2024
Sangamo Therapeutics, Inc. Q2 2024 Earnings Call Transcript
at insidermonkey.com 
Yahoo News
6th of August 2024
Roche licenses Sangamos technology for another shot at Alzheimers drugs
at finance.yahoo.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Sangamo Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Sangamo Therapeutics' short interest history, or implied volatility extrapolated from Sangamo Therapeutics options trading.
When determining whether Sangamo Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sangamo Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sangamo Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sangamo Therapeutics Stock:
Check out Sangamo Therapeutics Backtesting and Sangamo Therapeutics Hype Analysis.
To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.
You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sangamo Therapeutics. If investors know Sangamo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sangamo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.38)
Revenue Per Share
0.066
Quarterly Revenue Growth
(0.95)
Return On Assets
(0.58)
Return On Equity
(1.94)
The market value of Sangamo Therapeutics is measured differently than its book value, which is the value of Sangamo that is recorded on the company's balance sheet. Investors also form their own opinion of Sangamo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sangamo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sangamo Therapeutics' market value can be influenced by many factors that don't directly affect Sangamo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sangamo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sangamo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sangamo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.